179420-67-8Relevant articles and documents
TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
-
Page/Page column 86, (2010/11/28)
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.
Efficient synthesis of 4-(3-fluoro-5-{[4-(2-methyl-1h-imidazol-1-yl)benzyl] -oxy}phenyl)tetrahydro-2h-pyran-4-carboxamide, a novel 5-lipoxygenase inhibitor
Mano, Takashi,Stevens, Rodney W.,Nakao, Kazunari,Okumura, Yoshiyuki,Kawamura, Kiyoshi,Ando, Akemi,Matsuoka, Yoko
, p. 2625 - 2628 (2007/10/03)
An efficient synthesis of 1, a novel orally active 5-lipoxygenase inhibitor, was developed. Key features of the modified synthetic route include facile construction of the benzyl phenyl ether moiety by nucleophilic aromatic substitution and THP ring by cyclization, and base-promoted hydrolysis of the nitrile group to carboxamide. The improved three-step synthesis provides 25 g of 1 for pre-clinical toxicology studies in a total yield of 59%.
4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]phenyl]-3,4,5, 6-tetrahydro-2H-pyran-4-carboxamide, an Orally Active Inhibitor of 5-Lipoxygenase with Improved Pharmacokinetic and Toxicology Characteristics
Mano, Takashi,Okumura, Yoshiyuki,Sakakibara, Minoru,Okumura, Takako,Tamura, Tetsuya,Miyamoto, Kimitaka,Stevens, Rodney W.
, p. 720 - 725 (2007/10/03)
Described herein are structure- activity relationships (SARs) of 4-[5-fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]-phenyl]-4-methoxy-3,4,5, 6-tetrahydro-2H-pyran (1, CJ-12,918), an imidazole 5-lipoxygenase (5-LO) inhibitor. When 1 was tested in precl
5-lipoxygenase inhibitors
-
, (2008/06/13)
Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having the following formula I: STR1 and the pharmaceutically acceptable salts thereof, wherein Ar1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, py